via Georgia State University
Treatment of SARS-CoV-2 infection with a new antiviral drug, MK-4482/EIDD-2801 or Molnupiravir, completely suppresses virus transmission within 24 hours, researchers in the Institute for Biomedical Sciences at Georgia State University have discovered.
The group led by Dr. Richard Plemper, Distinguished University Professor at Georgia State, originally discovered that the drug is potent against influenza viruses.
“This is the first demonstration of an orally available drug to rapidly block SARS-CoV-2 transmission,” said Plemper. “MK-4482/EIDD-2801 could be game-changing.”
Interrupting widespread community transmission of SARS-CoV-2 until mass vaccination is available is paramount to managing COVID-19 and mitigating the catastrophic consequences of the pandemic.
Because the drug can be taken by mouth, treatment can be started early for a potentially three-fold benefit: inhibit patients’ progress to severe disease, shorten the infectious phase to ease the emotional and socioeconomic toll of prolonged patient isolation and rapidly silence local outbreaks.
“We noted early on that MK-4482/EIDD-2801 has broad-spectrum activity against respiratory RNA viruses and that treating infected animals by mouth with the drug lowers the amount of shed viral particles by several orders of magnitude, dramatically reducing transmission,” said Plemper. “These properties made MK-4482/EIDD/2801 a powerful candidate for pharmacologic control of COVID-19.”
In the study published in Nature Microbiology, Plemper’s team repurposed MK-4482/EIDD-2801 against SARS-CoV-2 and used a ferret model to test the effect of the drug on halting virus spread.
“We believe ferrets are a relevant transmission model because they readily spread SARS-CoV-2, but mostly do not develop severe disease, which closely resembles SARS-CoV-2 spread in young adults,” said Dr. Robert Cox, a postdoctoral fellow in the Plemper group and a co-lead author of the study.
The researchers infected ferrets with SARS-CoV-2 and initiated treatment with MK-4482/EIDD-2801 when the animals started to shed virus from the nose.
“When we co-housed those infected and then treated source animals with untreated contact ferrets in the same cage, none of the contacts became infected,” said Josef Wolf, a doctoral student in the Plemper lab and co-lead author of the study. By comparison, all contacts of source ferrets that had received placebo became infected.
If these ferret-based data translate to humans, COVID-19 patients treated with the drug could become non-infectious within 24 hours after the beginning of treatment.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Molnupiravir
- COVID-19 drugs: Are there any that work?
C OVID-19 medicine can help people who are at risk of, diagnosed with, or have symptoms of coronavirus disease 2019 (COVID-19). The medicine helps manage symptoms, stop the virus that causes COVID-19 ...
- A better COVID treatment for the immunocompromised? Researchers create a non-toxic potential alternative to Paxlovid
A combination of two antiviral compounds may be a promising alternative to Paxlovid when treating COVID-19 in immunocompromised patients, according to Karen S. Anderson, Ph.D., professor of ...
- MedEthix leverages synergy to ease molnupiravir access
FILIPINO pharmaceutical company MedEthix went beyond its way as the first importer to secure from the Food and Drug Administration the compassionate special permit (CSP) for molnupiravir — an oral ...
- Revolutionary new coronavirus drug might cure COVID-19 in just 5 days
Researchers from the Georgia State University announced in early December the extremely promising findings of a coronavirus study looking at the MK-4482/EIDD-2801 drug, also known as molnupiravir.
- Study uncovers consequences of molnupiravir use to treat COVID-19
A collaboration between the University of Tasmania and Royal Hobart Hospital Pathology has revealed the consequences of using molnupiravir to treat COVID-19. Published in The Lancet Microbe ...
Go deeper with Google Headlines on:
Molnupiravir
[google_news title=”” keyword=”Molnupiravir” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
SARS-CoV-2 transmission
- MERS Covid resurfaces in Saudi Arabia; should you be worried?
According to Dr Syed Abdul Aleem, Consultant – Pulmonology, CARE Hospitals, Musheerabad, Hyderabad , MERS-CoV (i.e., Middle East Respiratory Syndrome Coronavirus) is a viral respiratory illness caused ...
- 91 cases of new Covid variant KP.2 identified in Maharashtra
MUMBAI: The state has identified 91 cases of the new Covid-19 Omicron subvariant KP.2 that has outpaced the previously circulating JN.1 variant and is now driving cases in several countries. Pune has ...
- "FLiRT" COVID variants are now more than a third of U.S. cases. Scientists share what we know about them so far.
More than a third of COVID-19 cases in the U.S. are now estimated to be from a new, fast-growing member of a group of so-called "FLiRT" variants, nicknamed for their small but distinctive changes ...
- Symptoms, spread and more: What to know about new COVID ‘FLiRT' variants
A new series of COVID variants, nicknamed the "FLiRT" variants, are being tracked by U.S. health officials, according to the Centers for Disease Control and Prevention.
- There's a new COVID-19 variant called FLiRT: Here's what you need to know about it
There's a new COVID variant nicknamed "FLiRT." Here's what you need to know about the variant, including the symptoms.
Go deeper with Google Headlines on:
SARS-CoV-2 transmission
[google_news title=”” keyword=”SARS-CoV-2 transmission” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]